Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium

Kanthi Bangalore Krishna, John S. Fuqua, Alan D. Rogol, Karen O. Klein, Jadranka Popovic, Christopher P. Houk, Evangelia Charmandari, Peter A. Lee

Research output: Contribution to journalReview article

Abstract

This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.

Original languageEnglish (US)
JournalHormone Research in Paediatrics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Precocious Puberty
Gonadotropin-Releasing Hormone
Publications
Transgender Persons
Pediatrics
Endocrinology
Expert Testimony
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adolescent
  • Adolescents
  • Children
  • Children
  • Gonadotropin-releasing hormone analogs
  • Precocious puberty
  • Precocious puberty
  • Transgender
  • Transgenderanalogs

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Use of Gonadotropin-Releasing Hormone Analogs in Children : Update by an International Consortium. / Bangalore Krishna, Kanthi; Fuqua, John S.; Rogol, Alan D.; Klein, Karen O.; Popovic, Jadranka; Houk, Christopher P.; Charmandari, Evangelia; Lee, Peter A.

In: Hormone Research in Paediatrics, 01.01.2019.

Research output: Contribution to journalReview article

Bangalore Krishna, Kanthi ; Fuqua, John S. ; Rogol, Alan D. ; Klein, Karen O. ; Popovic, Jadranka ; Houk, Christopher P. ; Charmandari, Evangelia ; Lee, Peter A. / Use of Gonadotropin-Releasing Hormone Analogs in Children : Update by an International Consortium. In: Hormone Research in Paediatrics. 2019.
@article{ddf9b5171fc147a193ad776000797f4c,
title = "Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium",
abstract = "This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.",
keywords = "Adolescent, Adolescents, Children, Children, Gonadotropin-releasing hormone analogs, Precocious puberty, Precocious puberty, Transgender, Transgenderanalogs",
author = "{Bangalore Krishna}, Kanthi and Fuqua, {John S.} and Rogol, {Alan D.} and Klein, {Karen O.} and Jadranka Popovic and Houk, {Christopher P.} and Evangelia Charmandari and Lee, {Peter A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000501336",
language = "English (US)",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Use of Gonadotropin-Releasing Hormone Analogs in Children

T2 - Update by an International Consortium

AU - Bangalore Krishna, Kanthi

AU - Fuqua, John S.

AU - Rogol, Alan D.

AU - Klein, Karen O.

AU - Popovic, Jadranka

AU - Houk, Christopher P.

AU - Charmandari, Evangelia

AU - Lee, Peter A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.

AB - This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.

KW - Adolescent

KW - Adolescents

KW - Children

KW - Children

KW - Gonadotropin-releasing hormone analogs

KW - Precocious puberty

KW - Precocious puberty

KW - Transgender

KW - Transgenderanalogs

UR - http://www.scopus.com/inward/record.url?scp=85069755144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069755144&partnerID=8YFLogxK

U2 - 10.1159/000501336

DO - 10.1159/000501336

M3 - Review article

AN - SCOPUS:85069755144

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

ER -